8-K: NeuroPace Reports Strong Q2 2026, Raises Revenue Guidance

NeuroPace announced robust second quarter 2026 financial results, driven by significant RNS revenue growth, and has increased its full-year revenue guidance.

Summary

• NeuroPace reported total revenue of $22.8 million for the second quarter of 2026, a 17% increase year-over-year.
• RNS System revenue reached $22.5 million, marking a 21.3% growth compared to Q2 2025.
• The net loss for Q2 2026 narrowed to $6.2 million from $10.0 million in Q2 2025.
• Adjusted EBITDA loss improved to $2.8 million, an increase of $2.1 million from the prior year's loss of $4.9 million.
• Full-year 2026 total revenue guidance has been raised to $99.5 million $101.5 million, anticipating 21%-23% growth in core RNS revenue.
• The company is on track for its FDA SIR meeting regarding the IGE PMA supplement, supported by NAUTILUS data showing a 100% median reduction in GTC seizures in evaluable patients.
• NeuroPace launched ECoG Assistant, an AI-based clinical decision support tool.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with revenue growth exceeding expectations and improved financial guidance for the full year, alongside promising clinical data.

Positives

• Total revenue increased by 17% to $22.8 million in Q2 2026.
• RNS System revenue grew by 21.3% to $22.5 million in Q2 2026.
• Net loss decreased to $6.2 million in Q2 2026 from $10.0 million in Q2 2025.
• Adjusted EBITDA loss improved by $2.1 million to $2.8 million in Q2 2026.
• Full-year 2026 revenue guidance increased to $99.5 million $101.5 million.
• Full-year non-GAAP gross margin guidance increased to 82.0% 83.0%.
• Full-year Adjusted EBITDA guidance improved to ($7.5) million ($8.5) million.
• Published 18-month NAUTILUS results in Epilepsia showing a 77% median reduction in GTC seizures.
• Reached new all-time highs in active prescribers, accounts, and patient pipeline.

Negatives

• Non-GAAP gross margin slightly declined year-over-year from 84.0% to 83.4% due to higher material costs.
• GAAP net loss from continuing operations was $6.2 million in Q2 2026.
• Cash, cash equivalents, short-term investments, and restricted cash decreased to $51.9 million from $54.8 million at the end of the prior quarter.

Risks

• Uncertainties related to market acceptance and adoption of NeuroPace's RNS System.
• Risks that operating expenses could be higher than anticipated and cash resources could be used sooner than expected.
• Risks that gross margin may be lower than forecast.
• Risks related to the pricing of the RNS System and availability of adequate reimbursement.
• Risks related to regulatory compliance and expectations for regulatory approvals to expand the market.
• Risks related to product development, including AI-powered software and next-generation devices.
• Risks related to reliance on contractors and third-party suppliers.

Future Outlook

The company has raised its full-year 2026 total revenue guidance to $99.5 million to $101.5 million, expecting 21% to 23% growth in core RNS revenue. Full-year non-GAAP gross margin guidance has also been increased to 82.0% 83.0%, and Adjusted EBITDA guidance is now between ($7.5) million and ($8.5) million. This outlook excludes any contribution from the idiopathic generalized epilepsy indication expansion.

Management Comments

• "Second-quarter performance showed continued momentum in our core RNS business driven by increased adoption within our current focal epilepsy indication," said Joel Becker, Chief Executive Officer of NeuroPace.
• "We also maintained strong financial discipline while continuing to invest in the long-term growth of the business and advance our product roadmap."
• "The launch of ECoG Assistant marked an important first-of-its-kind step in extending the differentiated capabilities of the RNS System, building on NeuroPaces unique ability to continuously monitor and record each patients intracranial EEG data, efficiently identify ECoGs of interest and support more individualized therapy, reinforcing a data advantage that other neuromodulation platforms cannot replicate."
• "Looking ahead, we remain focused on sustaining momentum in our core business. Additionally, we look forward to continuing our engagement with the FDA regarding the path forward for our IGE PMA Panel Track supplement and remain on track with our clinical and regulatory timelines."

Industry Context

StockSavvy.ai notes that NeuroPace's performance aligns with a trend of increasing adoption for specialized medical devices targeting chronic conditions. The company's focus on AI-driven tools and robust clinical data for regulatory submissions reflects broader industry advancements in leveraging technology for improved patient outcomes and market differentiation.

Stakeholder Impact

• Shareholders: Positive impact from raised revenue guidance and improved financial outlook.
• Patients: Potential for improved treatment outcomes with the RNS System and new AI tools.
• Physicians: Enhanced clinical decision-making support through the ECoG Assistant.
• Regulators (FDA): Continued engagement on PMA supplement for IGE indication.

Next Steps

• Continue engagement with the FDA regarding the IGE PMA Panel Track supplement.
• Sustain momentum in the core RNS business.
• Advance product roadmap, including AI-enabled tools and next-generation platforms.

Key Dates

Recommendation

The company shows strong operational and revenue growth, with positive clinical data and improved guidance. However, the continued net losses and significant cash burn, coupled with long-term debt, warrant a 'hold' rating until profitability is more clearly on the horizon or further de-risking of the regulatory path occurs.

Keywords

epilepsy, neuromodulation, RNS System, medical device, FDA, seizures, drug-resistant epilepsy, clinical trial